DBAG share a “top pick”, and included in the “Best of 2022”

Average target price rises to 50.90 euros

Following publication of DBAG’s results for the financial year 2020/2021, the analysts covering our share have confirmed their investment ratings and in some cases raised their target price. DBAG’s average target price is now 50.90 euros, up from 49.57 euros:





Target price

9 Dec 2021

J.P. Morgan Cazenove

Christopher Brown



7 Dec 2021

Warburg Research

Cansu Tatar


53,00 €

6 Dec 2021

Hauck & Aufhäuser

Marie-Thérèse Grübner


55,00 €

3 Dec 2021

SRC Research

Stefan Scharff/Christopher Mehl


50,00 €

2 Dec 2021

Kepler Cheuvreux

Sven Sauer


50,00 €

2 Dec 2021

Jefferies International

Tom Mills


47,00 €

2 Dec 2021

Baader Helvea Equity Research

Tim Dawson


50,40 €

Baader Helvea includes DBAG’s share in its current list of "top picks" and views it as one of the best investment opportunities for 2022: “In our opinion, DBAG remains a first-class investment opportunity within the listed private equity sector. It maintains a leading position in the MBO segment of the German Mittelstand, and is well placed to take advantage of additional opportunities across the Germany, Austria and Switzerland (“DACH”) region, as well as through its recently opened office in Italy. The bank states that “following the publication of results for the financial year 2020/2021, we maintain our Buy rating and our target price also remains unchanged at 50.40 euros".

Warburg Research lists DBAG shares among the nine stocks ("high conviction ideas") that make up the Bank's "Monthly conviction list" in December from among the approximately 200 stocks that the Bank regularly follows.

Research reports are generally aimed at professional investors and are therefore not available to the public. Legal restrictions mean that only Warburg Research, SRC Research and Edison Research reports are available to download from our website. It shows a regularly updated table of analyst recommendations and price targets. Legal restrictions mean that Edison Research does not issue an investment opinion and J.P. Morgan Cazenove does not publish a target price for our share.